Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00157118 | Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency | PHASE2 | COMPLETED | 18 | — | — | Aug 22, 2003 | Mar 17, 2005 | May 5, 2021 | 12 | United States |
| Name | Type | Description |
|---|---|---|
| Protein C Concentrate (Human) Vapor Heated | DRUG | - |
Inclusion Criteria: * Newborn subjects \<= 6 months of age: diagnosis of severe congenital protein C deficiency, with documented functional protein C level \< 20%. If a genetic diagnosis is not available prior to initiation of Protein C Concentrate treatment, a documented family history of protein ...